Free Trial
NASDAQ:UNCY

Unicycive Therapeutics 3/27/2025 Earnings Report

Unicycive Therapeutics logo
$0.64 0.00 (0.00%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.64 0.00 (0.00%)
As of 04/25/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unicycive Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A

Unicycive Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unicycive Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Unicycive Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Unicycive Therapeutics Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Unicycive Therapeutics initiated with a Buy at Guggenheim
Unicycive presents new patient-level data from Phase 2 study of OLC
See More Unicycive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email.

About Unicycive Therapeutics

Unicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

View Unicycive Therapeutics Profile

More Earnings Resources from MarketBeat